Pelthos Therapeutics (PTHS) Fundamental Analysis: Revenue, Earnings & Valuation

3.71 / 10

Netural

PTHS scores poorly on Asset-MV (-0.5066) and Revenue-MV (-1.4356), placing them in the weakest performance quartiles, while Profit-MV (0.4743) and Net income-Revenue (-0.1516) are moderate. Gross profit margin is high at 68.73%, but inventory and asset turnover are suboptimal. The composite fundamental score is 3.7/10, indicating inadequate positioning and a negative outlook.

Analysis Checks(7/10)

Revenue-MV

Value-1.44

Score1/3

Weight10.63%

1M Return5.63%

Inventory turnover ratio

Value0.19

Score3/3

Weight9.74%

1M Return5.89%

Gross profit margin (%)

Value68.73

Score1/3

Weight0.31%

1M Return0.22%

Profit-MV

Value0.47

Score2/3

Weight14.88%

1M Return7.95%

Net income-Revenue

Value-0.15

Score2/3

Weight15.08%

1M Return8.04%

PB-ROE

Value0.30

Score3/3

Weight22.38%

1M Return11.66%

Current assets turnover ratio

Value0.29

Score2/3

Weight2.64%

1M Return1.75%

Fixed assets turnover ratio

Value1.10

Score3/3

Weight2.25%

1M Return1.53%

Asset-MV

Value-0.51

Score0/3

Weight7.35%

1M Return4.17%

Cash-MV

Value-0.07

Score2/3

Weight14.74%

1M Return7.78%

Is PTHS undervalued or overvalued?

PTHS scores 3.71/10 on fundamentals and holds a Fair valuation at present. Backed by its -77.98% ROE, 0.00% net margin, -3.15 P/E ratio, 1.28 P/B ratio, and 50.33% earnings growth, these metrics solidify its Netural investment rating.